Friday, October 12, 2012 (Last Updated: 10/15/2012)
Abraxane was first approved in 2005 to treat breast cancer.
In a new clinical study of 1,038 people, the most common adverse reactions to the drug were anemia, loss of hair, nausea, fatigue, loss of appetite, irregularity, rash, and swelling.
Abraxane is produced by Celgene Corp., based in Summit, N.J.
For more information about non-small cell lung cancer, visit the U.S. National Cancer Institute.
Hematology & Oncology
Copyright © 2012 HealthDay. All rights reserved.